Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 1, open-label, two-period, one-sequence, crossover study to evaluate effect of Omeprazole on the pharmacokinetics, safety, and tolerability of Roxadustat in healthy subjects

Next Previous
Trial Profile

A phase 1, open-label, two-period, one-sequence, crossover study to evaluate effect of Omeprazole on the pharmacokinetics, safety, and tolerability of Roxadustat in healthy subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 18 May 2018

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Roxadustat (Primary) ; Omeprazole
  • Indications Anaemia
  • Focus Pharmacokinetics
  • Sponsors Astellas Pharma

Most Recent Events

  • 18 May 2018 New trial record
  • 11 May 2018 According to results presented at the European Journal of Drug Metabolism and Pharmacokinetics, the study was conducted at the single center (PAREXEL Early Phase Clinical Unit) in Berlin, Germany.
  • 11 May 2018 Results assessing effect of omeprazole on pharmacokinetics, safety and tolerability of Roxadustat were published in the European Journal of Drug Metabolism and Pharmacokinetics.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top